- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Awareness, Progress, and the Search for Answers Thyroid Cancer Awareness Month is a chance to broaden our understanding not only of thyroid cancer, but also of the clinical considerations and decision-making pathways that can arise when a thyroid nodule is discovered. The path forward may involve several tests and conversations centered on a question that […] The post Advancing Thyroid Nodule Care This Thyroid Cancer Awareness Month appeared first on Veracyte.
For the many patients and families navigating prostate cancer, Prostate Cancer Awareness Month is a time to focus on the people behind every diagnosis and the questions, decisions, and care teams that shape each patient’s path forward. It is also an opportunity to look at how tools such as prostate cancer genomic testing are helping […] The post From Awareness to Answers: Helping Personalize Care this Prostate Cancer Awareness Month appeared first on Veracyte.
For over a decade, Veracyte has advanced the science of thyroid nodule molecular diagnostics and has helped approximately 400,000 patients with indeterminate thyroid nodules avoid unnecessary surgery or experience more personalized treatment. The next step in thyroid molecular genomic analysis is to further personalize treatment for patients with molecularly suspicious nodules, which requires going beyond […] The post Expanding the Afirma GRID proprietary research-use-only database appeared first on Veracyte.
How advances in research are bringing new hope   May is Bladder Cancer Awareness Month, a moment to recognize the people behind every diagnosis: patients navigating difficult decisions, the friends and family offering support along the way, and healthcare professionals dedicated to delivering the best possible care.   Alongside this shared commitment to care, ongoing advances from the […] The post The future of personalized bladder cancer care appeared first on Veracyte.
October is Breast Cancer Awareness Month, a time to honor the patients and their families worldwide whose lives have been impacted by breast cancer and to recognize the progress being made to combat this pervasive disease. Globally, breast cancer remains the most common cancer among women, with over 2.3 million new cases reported in 2022. […] The post Fighting breast cancer with genomic testing appeared first on Veracyte.
September is Prostate Cancer Awareness Month, a dedicated time to recognize the brave individuals impacted by the disease and honor the ongoing research and innovation reshaping patient outcomes. Nearly 314,000 patients in the United States will be diagnosed with prostate cancer this year, and the disease will claim approximately 35,770 lives, according to the American Cancer […] The post Innovation in prostate cancer care appeared first on Veracyte.
Afirma GSC Shows Value in Ruling Out Malignancy in Indeterminate Thyroid Nodules (ITN) An indeterminate thyroid nodule (ITN) carries a ~25% risk of malignancy (ROM), and historically diagnostic surgery for ITNs revealed a benign histopathology in 75% of cases. Molecular testing attempts to help prevent unnecessary surgeries with a focus on “rule-out” metrics such as […] The post Real-world utility with Afirma GSC Benign Results appeared first on Veracyte.
May is Bladder Cancer Awareness Month—a meaningful time to spotlight a disease that will be diagnosed in nearly 85,000 people in the U.S. this year alone and is expected to claim more than 17,000 lives, according to the American Cancer Society. Unfortunately, the bladder cancer patient journey is rarely straightforward. From vague initial symptoms to […] The post Bringing clarity to bladder cancer care appeared first on Veracyte.
A Meta-analysis Can Provide Data Synthesis Across Several Sites An indeterminate thyroid nodule (ITN) carries a ~25% risk of malignancy (ROM), and molecular diagnostics can play a key role in ruling out cancer for the majority of ITN nodules that are benign. Molecular diagnostic tests are designed to confidently rule out malignancy in these nodules […] The post Afirma GSC: Benign Result appeared first on Veracyte.
Previously we’ve discussed how cancer isn’t a single mutation event. Similarly, cancer behavior isn’t limited to cancer cell activity alone. This view is devoid of the context that surrounds and influences the cancer cells – known as the “tumor microenvironment,” or “TME.” English surgeon and pathologist Stephen Paget proposed a “seed and soil” hypothesis which describes cancer […] The post Afirma GSC: The tumor microenvironment appeared first on Veracyte.
